Skip to main content

Main menu

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
  • Other Publications
    • The Journal of Applied Laboratory Medicine

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Clinical Chemistry
  • Other Publications
    • The Journal of Applied Laboratory Medicine
  • Subscribe
  • My alerts
  • Log in
Clinical Chemistry

Advanced Search

  • Home
  • About
    • Clinical Chemistry
    • Editorial Board
    • Most Read
    • Most Cited
    • Alerts
    • CE Credits
  • Articles
    • Current Issue
    • Early Release
    • Future Table of Contents
    • Archive
    • Browse by Subject
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Advertisers
    • Permissions & Reprints
  • Resources
    • AACC Learning Lab
    • Clinical Chemistry Trainee Council
    • Clinical Case Studies
    • Clinical Chemistry Guide to Scientific Writing
    • Clinical Chemistry Guide to Manuscript Review
    • Journal Club
    • Podcasts
    • Q&A
    • Translated Content
  • Abstracts
  • Submit
  • Contact
LetterLetters to the Editor

Profile of Serum Pregnancy-Associated Plasma Protein A after Sustained Subcutaneous Low Molecular Weight Heparin Administration in Patients with Cerebrovascular Diseases

Shun Wang, Lili Wang, Xin Zhang, Chuanxin Wang, Wei Wu, Xuhua Zhang, Zhaogang Dong, Lutao Du
DOI: 10.1373/clinchem.2010.152702 Published February 2011
Shun Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lili Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chuanxin Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cxwang@sdu.edu.cn
Wei Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuhua Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaogang Dong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutao Du
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editor:

Pregnancy-associated plasma protein A (PAPP-A),1 considered a surrogate marker of increased risk of unstable atherosclerosis and its complications (1, 2), is reversibly bound to the surfaces of several cell types because of heparin's effective competition for surface binding (3). Heparins, however, especially low molecular weight heparins (LMWH), are routinely used for the treatment and prevention of thromboembolism. Because of the observation that intravenous administration of LMWH and heparin elicits a rapid increase in serum PAPP-A (4), we investigated the time profile of the effect of subcutaneous LMWH administration on PAPP-A concentration in a cerebrovascular disorder population.

Blood samples were collected from 10 patients with ischemic stroke receiving 5000 U of subcutaneous LMWH twice daily (group A) and 10 patients with percutaneous carotid intervention receiving 4375 U heparin intravenously just before stenting (group B). For each patient in group A, the first venous blood sample was drawn after admission. We also collected samples at 3 h after LMWH administration on days 2, 3, and 7, and at 36 h after the last LMWH administration. For group B patients, samples were collected from the arterial sheath just before heparin administration and at 3, 5, 15, 40, 60, and 100 min after administration. The exact time of blood collection was recorded. Serum samples were separated by centrifugation at 1760g at 4 °C for 10 min and stored at −80 °C until analysis. The study protocol was approved by the Medical Ethics Committee of Qilu Hospital, and written informed consent was obtained from each patient. Serum total PAPP-A concentrations were measured with an ultrasensitive ELISA kit with polyclonal anti–PAPP-A antibody (DRG International). The intraassay CVs were 6.9% and 4.3% at 2.7 mU/L and 38.5 mU/L, respectively; interassay CVs were 9.4% and 5.9% at 2.2 mU/L and 36.5 mU/L, respectively.

Both LMWH and heparin administration increased serum PAPP-A concentrations (median, 1.8-fold in group A; median, 4.1-fold in group B). In group A, PAPP-A concentrations increased continuously during the period of LMWH administration (median change, from 12.03 mU/L to 21.80 mU/L; P = 0.002). This increase was followed by a normalization of the concentration after the drug was discontinued (Fig. 1). In group B, the PAPP-A concentration peaked within 5 min (median, 51.56 mU/L), remained increased for 15 min (median, 43.75 mU/L), and then decreased to 16.4 mU/L at 100 min. The response in group A was lower (peak median concentration, 21.80 mU/L vs 51.56 mU/L; P < 0.0001) but more sustained than in group B, possibly because of the differences of medication, dose, and administration patterns.

Fig. 1.
  • Download figure
  • Open in new tab
Fig. 1. PAPP-A concentration and LMWH concentration at baseline, day 1, day 2, and day 7.

PAPP-A and LMWH concentrations are presented as the median and 25th and 75th percentiles.

To document the relationship between sustained subcutaneous LMWH administration and serum PAPP-A concentration more clearly, we also measured the serum LMWH concentration by high-performance capillary electrophoresis. After subcutaneous injection twice daily for about 1 week, the LMWH concentration gradually increased (median, from 370 U/L on day 2 to 650 U/L on day 7; Fig. 1), which may have contributed to the gradually increasing PAPP-A concentration.

Because the LMWH concentration showed patient-to-patient variation (Fig. 1), we could not investigate whether the extent of heparin-induced PAPP-A release correlated with the atherosclerotic lesions of the vasculature. Furthermore, we found no significant correlations between the PAPP-A concentration after LMWH and heparin administration and age (P = 0.759 and 0.166, respectively). The PAPP-A concentration decreased slightly on the third day of the first part of the observation period, but the cause remains to be investigated. Although the PAPP-A response caused by heparins is clear, the origin of the increased PAPP-A is not. In addition to its role in the development of atherosclerotic lesions in animals, serum PAPP-A has also been reported as an indicator of the peripheral atherosclerotic burden in elderly patients (5). Because the increase in PAPP-A occurred within a few minutes after intravenous heparin injection, PAPP-A might be released from the vasculature with atheromatous plaques. Free PAPP-A is the major form of the PAPP-A increasing in the circulation (4), but only the surface-bound PAPP-A is active (3). Heparins could induce PAPP-A release from the cell surface and into the blood circulation. Therefore, heparins might be valuable in therapy for unstable atheromatous plaques.

Acknowledgments

We thank the Department of Neurology of Qilu Hospital for their help in sample collection.

Footnotes

  • ↵1 Nonstandard abbreviations:

    PAPP-A,
    pregnancy-associated plasma protein A;
    LMWH,
    low molecular weight heparin.

  • Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

  • Authors' Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest.

  • Role of Sponsor: The funding organizations played a direct role in the design of the study, choice of enrolled patients, review and interpretation of data, and preparation and final approval of the manuscript.

  • © 2010 The American Association for Clinical Chemistry

References

  1. 1.↵
    1. Bayes-Genis A,
    2. Conover CA,
    3. Overgaard MT,
    4. Bailey KR,
    5. Christiansen M,
    6. Holmes DR Jr.,
    7. et al
    . Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022–9.
    OpenUrlCrossRefPubMed Order article via Infotrieve
  2. 2.↵
    1. Fialová L,
    2. Pilecková N,
    3. Bauer J,
    4. Soukupová J,
    5. Kalousová M,
    6. Malbohan I,
    7. et al
    . Pregnancy-associated plasma protein-A in patients with cerebrovascular diseases—a pilot study. Prague Med Rep 2006;107:37–45.
    OpenUrlPubMed Order article via Infotrieve
  3. 3.↵
    1. Laursen LS,
    2. Overgaard MT,
    3. Weyer K,
    4. Boldt HB,
    5. Ebbesen P,
    6. Christiansen M,
    7. et al
    . Cell surface targeting of pregnancy-associated plasma protein A proteolytic activity. Reversible adhesion is mediated by two neighboring short consensus repeats. J Biol Chem 2002;277:47225–34.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Tertti R,
    2. Wittfooth S,
    3. Porela P,
    4. Airaksinen KE,
    5. Metsarinne K,
    6. Pettersson K
    . Intravenous administration of low molecular weight and unfractionated heparin elicits a rapid increase in serum pregnancy-associated plasma protein A. Clin Chem 2009;55:1214–7.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Mueller T,
    2. Dieplinger B,
    3. Poelz W,
    4. Haltmayer M
    . Increased pregnancy-associated plasma protein-A as a marker for peripheral atherosclerosis: results from the Linz Peripheral Arterial Disease Study. Clin Chem 2006;52:1096–103.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top

In this issue

Clinical Chemistry: 57 (3)
Vol. 57, Issue 3
March 2011
  • Table of Contents
  • Index by author
  • Table of Contents (PDF)
  • Cover (PDF)
  • Advertising (PDF)
  • Ed Board (PDF)
Print
Share
Profile of Serum Pregnancy-Associated Plasma Protein A after Sustained Subcutaneous Low Molecular Weight Heparin Administration in Patients with Cerebrovascular Diseases
Shun Wang, Lili Wang, Xin Zhang, Chuanxin Wang, Wei Wu, Xuhua Zhang, Zhaogang Dong, Lutao Du
Clinical Chemistry Mar 2011, 57 (3) 526-527; DOI: 10.1373/clinchem.2010.152702
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Profile of Serum Pregnancy-Associated Plasma Protein A after Sustained Subcutaneous Low Molecular Weight Heparin Administration in Patients with Cerebrovascular Diseases
Shun Wang, Lili Wang, Xin Zhang, Chuanxin Wang, Wei Wu, Xuhua Zhang, Zhaogang Dong, Lutao Du
Clinical Chemistry Mar 2011, 57 (3) 526-527; DOI: 10.1373/clinchem.2010.152702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing
  • Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests
  • In Reply
Show more Letters to the Editor

Similar Articles

Options

  • Home
  • About
  • Articles
  • Information for Authors
  • Resources
  • Abstracts
  • Submit
  • Contact
  • RSS

Other Publications

  • The Journal of Applied Laboratory Medicine
Footer logo

© 2019 American Association for Clinical Chemistry

Powered by HighWire